Delivered Q3 2025 revenue of $83 million Q3 2025 non-dermatologic revenue increased by 67$327-335 million from $310-320 million Announced launch of AdvanceAD-Tx™, the Company’s test designed to guide systemic treatment decision making in patients ages 12 and older with moderate-to-severe atopic dermatitis (AD) Conference call and w ...